— Know what they know.
/
Not Investment Advice

CTLT NYSE

Catalent, Inc.
1W: +2.0% 1M: +7.4% 3M: +5.2% 1Y: +53.0% 3Y: -48.1% 5Y: +21.6%
$63.48
Last traded 2024-12-17 — delisted
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · $11.5B mcap · 180M float · 1.24% daily turnover
Overview News Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings
Dividends Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest Supply Chain

Supply Chain Overview

1 relationships
0
As Filer
counterparties named
1
As Counterparty
mentioned by others
2025-10-08
Earliest Filing
2025-10-08
Latest Filing

Mentioned As Counterparty

1 mentions

Other companies that named CTLT in their SEC 8-K filings.

Filed By Relationship Summary Filing Date SEC
LSTA LISATA THERAPEUTICS, INC. licensee Lisata Therapeutics granted a non-exclusive license for its iRGD cyclic peptide technology to Catalent for use in its SM 2025-10-08 View
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text. Covers 2021–2026. View on SEC EDGAR

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms